Hikma Pharmaceuticals Faces Class I Recall for Acetaminophen Injection Due to Critical Label Mix-up
Hikma Pharmaceuticals USA Inc. has initiated a Class I recall for 31,400 bags of Acetaminophen Injection due to a critical label mix-up, where Dexmedetomidine HCl was found in Acetaminophen overwraps. This high-severity event demands immediate action from procurement and regulatory teams to mitigate patient safety risks and ensure supply chain integrity for this essential intravenous medication.
Critical Labeling Violation Triggers Class I Recall for Hikma's Acetaminophen Injection
Hikma Pharmaceuticals USA Inc. has initiated a voluntary Class I recall, designated D-0635-2024, for a significant quantity of its Acetaminophen Injection, 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose bags. This high-severity action, initiated on July 8, 2024, stems from a critical labeling mix-up: a bag containing Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was discovered inside an overwrap explicitly labeled for Acetaminophen Injection. The affected product, identified by Lot #24070381 with an expiration date of September 30, 2025, represents 31,400 bags distributed across Ohio (OH) and Puerto Rico (PR). For procurement directors and supply chain VPs, a Class I recall signifies that exposure to the mislabeled product could lead to serious adverse health consequences or even death. Administering Dexmedetomidine HCl, a potent sedative, instead of Acetaminophen, a common analgesic and antipyretic, poses immediate and severe risks, including respiratory depression, bradycardia, and hypotension, particularly in vulnerable patient populations. This incident necessitates immediate action to identify and quarantine any affected inventory, verify product identity, and ensure patient safety within your facilities. The product, with NDC 0143-9386-01, was manufactured by Hikma Farmaceutica (Portugal), SA, and distributed by Hikma Pharmaceuticals USA Inc. from Berkeley Heights, NJ, underscoring a potential systemic breakdown in quality control across the manufacturing and packaging process.
Hikma's Global Manufacturing and Distribution Network Under Scrutiny Following Recall
The Class I recall of Acetaminophen Injection places a spotlight on Hikma Pharmaceuticals USA Inc.'s operational integrity, specifically concerning its distribution from Cherry Hill, NJ, and the manufacturing processes at Hikma Farmaceutica (Portugal), SA. While Hikma Pharmaceuticals USA Inc. (located at 2 Esterbrook Ln, Cherry Hill, NJ 08003-4002) is the recalling firm, the actual manufacturing site in Portugal is the primary point of failure for this critical labeling mix-up. This distinction is crucial for regulatory affairs heads, as any subsequent FDA inspections or enforcement actions could extend beyond the U.S. distribution entity to the overseas manufacturing facility. The distribution pattern, limited to Ohio and Puerto Rico, helps define the immediate scope of impact but does not diminish the severity of the underlying quality system failure. For business development executives, this event raises questions about the robustness of Hikma’s global quality management systems and their ability to prevent such fundamental errors. Maintaining consistent quality across international manufacturing sites and ensuring rigorous packaging controls are paramount for pharmaceutical companies operating on a global scale. This incident underscores the necessity for comprehensive supplier audits that extend to manufacturing origins, irrespective of the distributing entity's location, to safeguard against similar product integrity breaches.
Supply Chain Exposure and Patient Safety Risks from Mislabeled Injectables
The mislabeling of 31,400 bags of Acetaminophen Injection with Dexmedetomidine HCl presents a significant supply chain exposure and acute patient safety risk for healthcare providers in Ohio and Puerto Rico. Procurement directors must recognize that this Class I recall demands immediate quarantine and verification of all Hikma Acetaminophen Injection, Lot #24070381. The potential for administering a sedative (Dexmedetomidine HCl) instead of an analgesic (Acetaminophen) can lead to severe adverse events, including profound sedation, respiratory depression, and hemodynamic instability, particularly in critically ill or pediatric patients. This scenario highlights a critical lapse in Good Manufacturing Practices (GMP) related to packaging and labeling controls, which are foundational to pharmaceutical quality assurance. Regulatory affairs heads should anticipate increased scrutiny on all Hikma products, potentially impacting future market authorizations or requiring enhanced post-market surveillance. Supply chain VPs must assess their internal protocols for receiving and verifying pharmaceutical products, especially high-volume injectables, to prevent such mislabeled items from reaching patient care areas. The financial and reputational costs associated with such a recall, including product retrieval, patient monitoring, and potential litigation, far outweigh the investment in robust quality control measures.
Identifying Alternative Suppliers for Critical Intravenous Acetaminophen
Given the Class I recall of Hikma Pharmaceuticals USA Inc.'s Acetaminophen Injection, procurement teams must urgently evaluate and diversify their sourcing strategies for this critical intravenous medication. While the ChemLifeIntel knowledge graph does not currently identify specific alternative suppliers for Acetaminophen Injection, this event underscores the imperative for procurement directors to proactively identify and qualify secondary and tertiary sources. Relying on a single supplier for essential hospital injectables like Acetaminophen creates significant vulnerability, as demonstrated by this high-severity recall. The qualification process for new pharmaceutical suppliers can be lengthy, involving rigorous audits, analytical testing, and regulatory approvals, often spanning several months to over a year. Business development executives should leverage this market disruption to explore new partnerships with manufacturers demonstrating robust quality systems and a strong regulatory compliance history. Diversifying the supplier base, ideally across different geographic regions, mitigates the risk of supply disruptions stemming from facility-specific issues, geopolitical events, or widespread regulatory actions. This incident serves as a stark reminder that supply chain resilience for critical care medications is not merely a best practice but a fundamental requirement for patient safety and operational continuity.
Regulatory Compliance Landscape: Hikma's Current Event Amid Broader FDA Scrutiny
While the provided knowledge graph does not detail Hikma Pharmaceuticals USA Inc.'s specific prior regulatory history, this Class I recall for Acetaminophen Injection represents a significant regulatory event that will undoubtedly draw intensified FDA scrutiny. A labeling mix-up of this magnitude indicates a fundamental breakdown in quality control and Good Manufacturing Practices (GMP) at the manufacturing level (Hikma Farmaceutica (Portugal), SA). Regulatory affairs heads should prepare for potential FDA follow-up inspections, not only at the U.S. distribution facility but critically at the Portuguese manufacturing site. The broader regulatory environment, as evidenced by recent parallel events such as Essential Wellness Pharma's Class II recall for sterility failures and Amgen facing an FDA hearing over market access, demonstrates the FDA's heightened vigilance across the pharmaceutical industry. This context suggests that any regulatory lapses, particularly those with direct patient safety implications like Hikma’s, will be met with rigorous enforcement. For business development executives, a tarnished regulatory record can impede new product launches, delay market access, and erode customer trust, impacting long-term commercial viability. Proactive engagement with regulatory bodies and transparent, swift corrective actions are essential to mitigate the long-term impact of such a high-profile recall.
Post-Recall Remediation and Future Regulatory Implications for Hikma
The ongoing status of Hikma Pharmaceuticals USA Inc.'s Class I recall for Acetaminophen Injection means the firm is actively engaged in removing the affected Lot #24070381 from the market. However, the regulatory implications extend far beyond product retrieval. Hikma is now obligated to conduct a comprehensive root cause analysis to identify precisely why Dexmedetomidine HCl was packaged in Acetaminophen overwraps and to implement robust corrective and preventive actions (CAPA) at the manufacturing facility in Portugal. Regulatory affairs heads must anticipate that the FDA will closely monitor these remediation efforts. Failure to demonstrate effective CAPA could lead to further enforcement actions, including potential Warning Letters, increased frequency of inspections, or even Import Alerts for products manufactured at the implicated facility. An Import Alert would severely restrict or halt the entry of products from Hikma Farmaceutica (Portugal), SA into the U.S. market, creating significant supply chain disruptions for any products sourced from that site. Supply chain VPs should model potential scenarios, including prolonged supply interruptions, and assess the impact on their inventory and patient care. Business development executives must understand that the resolution of this event will be critical for Hikma’s reputation and its ability to maintain and expand its market presence for injectable pharmaceuticals.